From Our Thought Leaders

Advancing Healthspan for All: Dr. Mehmood Khan Spotlights Aging Science Trends for 2025

  In an exclusive interview with BioPharma Boardroom, Dr. Mehmood Khan, Chief Executive Officer of Hevolution Foundation, shares insights into the trends shaping the field of aging research in 2025. From drug repurposing and epigenetic breakthr... Read more

12 December, 2024 | Thursday | News
Building a Sustainable Future: Cytiva’s 2025 Roadmap for Transforming Biopharma

As the biopharma industry continues to evolve, sustainability has emerged as a key driver of progress. Ryan Walker, Sustainability Program Leader at Cytiva, highlights the company’s holistic approach to advancing sustainability through innov... Read more

12 December, 2024 | Thursday | Opinion
Shaping the Future of Gene Therapy: Kerstin Pohl on Analytical Innovations for 2025

In a detailed interview with BioPharma BoardRoom, Kerstin Pohl, Senior Global Marketing Manager for Gene Therapy & Nucleic Acid at SCIEX, delves into the analytical challenges gene therapy developers face as the field evolves in 2025. From addres... Read more

12 December, 2024 | Thursday | Interaction
Redefining Precision Medicine: Demaris Mills on IDT’s Role in Precision Medicine and Gene Synthesis for 2025

In a thought-provoking Q&A with BioPharma BoardRoom, Demaris Mills, President of Integrated DNA Technologies (IDT), discusses the transformative advancements shaping gene editing and DNA synthesis as we approach 2025. From overcoming delivery cha... Read more

12 December, 2024 | Thursday | Interaction

Bio Finance

Eisai and Biogen Launch LEQEMBI® for Early Alzheimer's Treatment in South Korea

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced that the humanized anti-solu... Read more

28 November, 2024 | Thursday | News
Halozyme Withdraws €2.0 Billion Acquisition Proposal for Evotec Amid Lack of Engagement

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of &eu... Read more

25 November, 2024 | Monday | News

Contract Services

Wolfgang Wienand, CEO of Lonza, Outlines ‘One Lonza’ Strategy and 2025 Growth Targets

Lonza has provided an overview of its new “One Lonza” strategy and new organizational structure As Lonza focuses on its core CDMO1 business, it will exit the Capsules & Health Ingredients (CHI) business at the appropriate time an... Read more

12 December, 2024 | Thursday | News
Hovione Expands Global Footprint with Major Investments in U.S. and Europe

    Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in Europe and the USA. The investments at its East Windsor, New Jersey, and Ringaskiddy, Cor... Read more

27 November, 2024 | Wednesday | News

BioPharma Video

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close